Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 189

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury

Open access
Cardenas, Diana D., Nieshoff, Edward C., Suda, Kota, Goto, Shin-ichi, Sanin, Luis, Kaneko, Takehiko, Sporn, Jonathan, Parsons, Bruce, Soulsby, Matt, Yang, Ruoyong, Whalen, Ed, Scavone, Joseph M., Suzuki, Makoto M., Knapp, Lloyd E. · 2013 · Neurology

Abstract

OBJECTIVE: To assess the efficacy and tolerability of pregabalin for the treatment of central neuropathic pain after spinal cord injury (SCI). METHODS: Patients with chronic, below-level, neuropathic pain due to SCI were randomized to receive 150 to 600 mg/d pregabalin (n = 108) or matching placebo (n = 112) for 17 weeks. Pain was classified in relation to the neurologic level of injury, defined as the most caudal spinal cord segment with normal sensory and motor function, as above, at, or below level. The primary outcome measure was duration-adjusted average change in pain. Key secondary outcome measures included the change in mean pain score from baseline to end point, the percentage of patients with ≥30% reduction in mean pain score at end point, patient global impression of change scores at end point, and the change in mean pain-related sleep interference score from baseline to end point. Additional outcome measures included the medical outcomes study-sleep scale and the Hospital anxiety and depression scale. RESULTS: Pregabalin treatment resulted in statistically significant improvements over placebo for all primary and key secondary outcome measures. Significant pain improvement was evident as early as week 1 and was sustained throughout the treatment period. Adverse events were consistent with the known safety profile of pregabalin and were mostly mild to moderate in severity. Somnolence and dizziness were most frequently reported. CONCLUSIONS: This study demonstrates that pregabalin is effective and well tolerated in patients with neuropathic pain due to SCI. CLASSIFICATION OF EVIDENCE: This study provides class I evidence that pregabalin, 150 to 600 mg/d, is effective in reducing duration-adjusted average change in pain compared with baseline in patients with SCI over a 16-week period (p = 0.003, 95% confidence interval = -0.98, -0.20).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e318281546b

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 189

Metadata

Authors
Cardenas, D. D., Nieshoff, E. C., Suda, K., Goto, S.-I., Sanin, L., Kaneko, T., Sporn, J., Parsons, B., Soulsby, M., Yang, R., Whalen, E., Scavone, J. M., Suzuki, M. M., & Knapp, L. E.
Venue
Neurology
Published
2013-02-05
Volume
80
Issue
6
Pages
533-539
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2038826804
Cited by
189
References
1
FWCI
14.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. https://app.cochat.ai/papers/10.1212/wnl.0b013e318281546b
The paper
Cardenas, D. D., Nieshoff, E. C., Suda, K., Goto, S.-I., Sanin, L., Kaneko, T., Sporn, J., Parsons, B., Soulsby, M., Yang, R., Whalen, E., Scavone, J. M., Suzuki, M. M., & Knapp, L. E. (2013). A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology. https://doi.org/10.1212/wnl.0b013e318281546b

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.